The anti-B7-H3 mAb, MJ18, treatment induced substantial anti-tumour effect in vivo and significantly inhibited tumour growth (tumour volume at 2 weeks: anti-B7-H3 mAb, n=7, 23.6±12.2 mm3; control, n=5, 69.1±14.4 mm3; P=0.036; tumour volume at 4 weeks: anti-B7-H3 mAb, n=10, 144.6±13.3 mm3; control, n=9, 320.4±36.1 mm3; P=0.0002) (Figure 3). This evidence concerns the gene CD276 and neoplasm.